Drug Profile
LMP 420
Alternative Names: LMP-420Latest Information Update: 01 Mar 2011
Price :
$50
*
At a glance
- Originator University of North Carolina at Chapel Hill
- Developer LeukoMed
- Class Antirheumatics; Inorganic boron compounds; Purines
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Crohn's disease; Rheumatoid arthritis
Most Recent Events
- 17 May 2007 This programme is still in active development
- 27 Sep 2002 LMP 420 is available for licensing in the US and Europe (http://www.leukomed.com)
- 27 Sep 2002 Preclinical trials in Crohn's disease in USA (PO)